Concurrent Use of Subutex and Lorazepam: High-Risk Combination Requiring Extreme Caution
Subutex (buprenorphine) and lorazepam should generally NOT be taken together due to significant risk of respiratory depression, oversedation, and death. The FDA has issued a black box warning specifically against combining buprenorphine with benzodiazepines like lorazepam 1.
Critical Safety Concerns
The combination of buprenorphine and benzodiazepines creates additive central nervous system (CNS) depression that substantially increases mortality risk:
The FDA drug label for Subutex explicitly warns that deaths have occurred when buprenorphine is used concomitantly with benzodiazepines 1. This includes both intravenous misuse and prescribed oral use.
Patients must be warned of the potential danger of taking benzodiazepines while on Subutex, as serious overdose and death may occur 1.
CDC guidelines from 2016 found that concurrent benzodiazepine prescription with opioids (including buprenorphine) is associated with nearly quadrupling the risk of overdose death compared to opioids alone 2, 3.
When This Combination Might Be Considered
While the default position should be avoidance, there are limited circumstances where concurrent use may be necessary:
In pregnancy with opioid use disorder: Guidelines suggest that methadone may be more appropriate than buprenorphine if there is concurrent benzodiazepine use. However, buprenorphine should not be withheld from women concurrently using benzodiazepines if it is the only accessible or preferred pharmacotherapy - the FDA instead recommends careful medication management 4.
For patients already stable on both medications: If a patient becomes pregnant or presents already taking both medications, abrupt discontinuation of either could be harmful. The 2016 CDC guidelines note that because benzodiazepine withdrawal can be more dangerous than opioid withdrawal, it may be safer to taper opioids first if both medications need reduction 2.
Clinical Management If Concurrent Use Is Unavoidable
If you determine that both medications are absolutely necessary:
Use the lowest effective doses of both medications - dose reduction should be strongly considered 1
Ensure close monitoring for signs of respiratory depression, excessive sedation, and CNS depression 1
Prescribe naloxone for overdose reversal, though note that naloxone may not be fully effective in reversing buprenorphine-induced respiratory depression 1
Coordinate care between all prescribers - avoid situations where different clinicians prescribe each medication without awareness of the other 2, 3
Check your state's Prescription Drug Monitoring Program (PDMP) before prescribing to identify if the patient is already receiving benzodiazepines from another provider 3
Consider tapering the benzodiazepine gradually (25% dose reduction every 1-2 weeks is a commonly used safe schedule), with cognitive behavioral therapy to increase success rates 2
Common Clinical Pitfalls
Do not dismiss patients from care based on finding concurrent use - this constitutes patient abandonment and may drive patients to obtain medications from unsafe sources 2
Do not assume buprenorphine's partial agonist properties make it "safe" with benzodiazepines - the evidence clearly shows significant mortality risk 1, 2
Do not rely solely on patient self-report - studies show 17-38% of patients have prescribing discrepancies between medical records and PDMP data 5
Evidence Quality and Real-World Patterns
Research data shows that despite warnings, concurrent use remains common: approximately 1 in 6-8 buprenorphine prescriptions involves concomitant benzodiazepine use 6, 7. However, chronic concomitant use (>90 overlapping days) is rare, occurring in only 3% of treatment episodes 7, suggesting most clinicians recognize the risks.
The bottom line: This combination significantly increases risk of morbidity and mortality. Avoid concurrent prescribing whenever possible, and if unavoidable, implement intensive monitoring and risk mitigation strategies.